Low-intensity therapy very effective in Burkitt lymphoma

Low-Intensity Therapy Highly Effective in Burkitt's Lymphoma
Low-Intensity Therapy Highly Effective in Burkitt's Lymphoma

(HealthDay News) -- For patients with Burkitt's lymphoma, a low-intensity treatment consisting of infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (EPOCH-R) is highly effective, according to a study published in the Nov. 13 issue of the New England Journal of Medicine.

Kieron Dunleavy, M.D., from the National Cancer Institute in Bethesda, Md., and colleagues studied two EPOCH-R regimens in patients with Burkitt's lymphoma: a standard dose-adjusted combination in HIV-negative patients (DA-EPOCH-R group; 19 patients) and a lower-dose short-course combination with double dose of rituximab in HIV-positive patients (SC-EPOCH-RR group; 11 patients).

The researchers found that the main toxic events of fever and neutropenia were noted during 22 and 10 percent of DA-EPOCH-R and SC-EPOCH-RR cycles, respectively. In one patient, tumor lysis syndrome developed; there were no treatment-related deaths. Compared with the median cumulative doses in the DA-EPOCH-R group, those of doxorubicin-etoposide and cyclophosphamide were 47 and 57 percent lower, respectively, in the SC-EPOCH-RR group. The rates of freedom from progression of disease and overall survival were 95 and 100 percent, respectively, with DA-EPOCH-R over a median follow-up of 86 months. For the SC-EPOCH-RR group, the rates were 100 and 90 percent, respectively, over a median follow-up of 73 months. There were no cases of Burkitt's lymphoma death.

"In this uncontrolled prospective study, low-intensity EPOCH-R-based treatment was highly effective in adults with sporadic or immunodeficiency-associated Burkitt's lymphoma," the authors write.

Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs